DGAP-News: Cytos Biotechnology Second Quarter Report 2010
(firmenpresse) - Cytos Biotechnology AG / Half Year Results
22.07.2010 07:00
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Cytos Biotechnology Ltd Second Quarter Report 2010 as of June 30, 2010
Summary of important events in Q2 2010
- Placebo-controlled phase II study shows CYT003-QbG10 is safe and
efficacious for the treatment of allergic asthma
- Cytos Biotechnology sells platform technology for the identification of
monoclonal antibodies to Intercell for EUR 15 million
- Constitution of the Board of Directors after the Shareholder's Meeting
2010
- Harry Welten succeeds Jakob Schlapbach as CFO, Jakob Schlapbach elected
to the Board of Directors
- Upcoming events:
- Presentation at the European Respiratory Society 2010 Annual Congress,
September 18-22, 2010 in Barcelona, Spain
- Presentation at the Swiss Equity conference zurich, September 14/15,
2010 in Zurich, Switzerland
- Presentation at the Modern Vaccines/Adjuvants Formulation 2010
Conference, October 13-15, 2010 in Cannes, France
- Presentation at the Next Generation Vaccines Conference, October 21/22,
2010 in Vienna, Austria
- Financial summary
in CHF million YTD* 10 YTD* 09 Q2 10 Q2 09The complete Second Quarter Report 2010 can be downloaded on Cytos
Revenue 21.4 6.6 21.2 6.3
Net operating costs (14.4) (22.4) (7.5) (11.4)
Net income/(loss) 11.2 (18.0) 15.0 (6.2)
06/30/10 12/31/09
Cash, cash equivalents, 56.6 60.5
financial assets
and trade receivables
Nominal value of the convertible 41.1 57.1
bonds not held by
Cytos Biotechnology Ltd
Full-time employees (number) 76 85
* YTD = year to date January 1 - June
30
Biotechnology's website under the following link:
http://www.cytos.com/userfiles/file/Cytos_Q2_2010_E.pdf
Harry Welten, MBA
Chief Financial Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 46 46
Fax: +41 44 733 47 02
e-Mail: harry.welten(at)cytos.com
Website: www.cytos.com
22.07.2010 07:00 Ad hoc announcement, Financial News and Press Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open
Market in Frankfurt; Foreign Exchange(s) SIX
End of News DGAP News-Service
---------------------------------------------------------------------------Unternehmensinformation / Kurzprofil:
Datum: 22.07.2010 - 07:00 Uhr
Sprache: Deutsch
News-ID 24255
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 255 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos Biotechnology Second Quarter Report 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
